Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S450000
Reexamination Certificate
active
10467487
ABSTRACT:
The present invention relates to a compound of formula (I):corresponding pharmaceutical compositions, preparation processes, and/or methods of using the aforementioned compounds and/or compositions.
REFERENCES:
patent: 5892099 (1999-04-01), Maruyama et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: WO-003980 (2000-01-01), None
patent: WO 00/18744 (2000-04-01), None
patent: WO-0018744 (2000-04-01), None
patent: WO-0021532 (2000-04-01), None
patent: WO 01/10426 (2001-02-01), None
Rufer, et al., Eur. J. Med. Chem, 1978, vol. 13, No. 2, pp. 193-198.
Congreve Miles Stuart
Giblin Gerard Martin Paul
Walker Ann Louise
Glaxo Group Limited
Grazier Nyeemah
McKane Joseph K.
Young J. Scott
LandOfFree
Benzo[f]isoindole derivatives with affinity to the EP4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzo[f]isoindole derivatives with affinity to the EP4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzo[f]isoindole derivatives with affinity to the EP4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737280